Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 106

  • Showing results for besnier jm. Search instead for BesnierF JM (1 item)
1.

Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial.

Cambau E, Durand-Zaleski I, Bretagne S, Brun-Buisson C, Cordonnier C, Duval X, Herwegh S, Pottecher J, Courcol R, Bastuji-Garin S; EVAMICA study team.

Intensive Care Med. 2017 Apr 3. doi: 10.1007/s00134-017-4766-4. [Epub ahead of print]

PMID:
28374097
2.

Tobacco differentially affects the clinical-biological phenotypes of ANCA-associated vasculitides.

Benarous L, Terrier B, Puéchal X, Dunogué B, Cohen P, Le Jeunne C, Mouthon L, Guillevin L; French Vasculitis Study Group (FVSG).

Clin Exp Rheumatol. 2015 Mar-Apr;33(2 Suppl 89):S-116-21. Epub 2015 May 26.

PMID:
26016761
3.

Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial.

Bernard L, Dinh A, Ghout I, Simo D, Zeller V, Issartel B, Le Moing V, Belmatoug N, Lesprit P, Bru JP, Therby A, Bouhour D, Dénes E, Debard A, Chirouze C, Fèvre K, Dupon M, Aegerter P, Mulleman D; Duration of Treatment for Spondylodiscitis (DTS) study group.

Lancet. 2015 Mar 7;385(9971):875-82. doi: 10.1016/S0140-6736(14)61233-2. Epub 2014 Nov 5.

PMID:
25468170
4.

Escherichia coli bacteremia in children: age and portal of entry are the main predictors of severity.

Burdet C, Clermont O, Bonacorsi S, Laouénan C, Bingen E, Aujard Y, Mentré F, Lefort A, Denamur E; COLIBAFI Group.

Pediatr Infect Dis J. 2014 Aug;33(8):872-9. doi: 10.1097/INF.0000000000000309.

PMID:
25222308
5.

Escherichia coli bacteraemia in pregnant women is life-threatening for foetuses.

Surgers L, Bleibtreu A, Burdet C, Clermont O, Laouénan C, Lefort A, Mentré F, Carbonne B, Bingen E, Meynard JL, Denamur E; COLIBAFI Group.

Clin Microbiol Infect. 2014 Dec;20(12):O1035-41. doi: 10.1111/1469-0691.12742. Epub 2014 Aug 11.

6.

Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee.

J Am Heart Assoc. 2014 May 28;3(3):e000844. doi: 10.1161/JAHA.114.000844.

7.

Factors associated with D-dimer levels in HIV-infected individuals.

Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee.

PLoS One. 2014 Mar 13;9(3):e90978. doi: 10.1371/journal.pone.0090978. eCollection 2014.

8.

Escherichia coli bacteraemia in adults: age-related differences in clinical and bacteriological characteristics, and outcome.

Roubaud Baudron C, Panhard X, Clermont O, Mentré F, Fantin B, Denamur E, Lefort A; COLIBAFI Group.

Epidemiol Infect. 2014 Dec;142(12):2672-83. doi: 10.1017/S0950268814000211. Epub 2014 Feb 20.

PMID:
24559489
9.

Complexity of Escherichia coli bacteremia pathophysiology evidenced by comparison of isolates from blood and portal of entry within single patients.

Clermont O, Glodt J, Burdet C, Pognard D, Lefort A, Branger C, Denamur E; COLIBAFI Group Members.

Int J Med Microbiol. 2013 Dec;303(8):529-32. doi: 10.1016/j.ijmm.2013.07.002. Epub 2013 Jul 17.

PMID:
23927963
10.

Is intrapartum intravenous zidovudine for prevention of mother-to-child HIV-1 transmission still useful in the combination antiretroviral therapy era?

Briand N, Warszawski J, Mandelbrot L, Dollfus C, Pannier E, Cravello L, Nguyen R, Matheron I, Winer N, Tubiana R, Rouzioux C, Faye A, Blanche S; ANRS-EPF CO1-CO11 Study Group.

Clin Infect Dis. 2013 Sep;57(6):903-14. doi: 10.1093/cid/cit374. Epub 2013 May 31.

PMID:
23728147
11.

A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.

Marcelin AG, Delaugerre C, Beaudoux C, Descamps D, Morand-Joubert L, Amiel C, Schneider V, Ferre V, Izopet J, Si-Mohamed A, Maillard A, Henquell C, Desbois D, Lazrek M, Signori-Schmuck A, Rogez S, Yerly S, Trabaud MA, Plantier JC, Fourati S, Houssaini A, Masquelier B, Calvez V, Flandre P; ANRS AC11 Resistance Group.

Int J Antimicrob Agents. 2013 Jul;42(1):42-7. doi: 10.1016/j.ijantimicag.2013.02.016. Epub 2013 Apr 4.

PMID:
23562640
12.

Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.

Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group.

PLoS One. 2013;8(2):e56249. doi: 10.1371/journal.pone.0056249. Epub 2013 Feb 15.

13.

Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.

Charpentier C, Joly V, Larrouy L, Fagard C, Visseaux B, de Verdière NC, Raffi F, Yeni P, Descamps D; ANRS 130 APOLLO Trial Study Group.

J Antimicrob Chemother. 2013 Mar;68(3):690-6. doi: 10.1093/jac/dks455. Epub 2012 Nov 14.

PMID:
23152480
14.

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort.

Comarmond C, Pagnoux C, Khellaf M, Cordier JF, Hamidou M, Viallard JF, Maurier F, Jouneau S, Bienvenu B, Puéchal X, Aumaître O, Le Guenno G, Le Quellec A, Cevallos R, Fain O, Godeau B, Seror R, Dunogué B, Mahr A, Guilpain P, Cohen P, Aouba A, Mouthon L, Guillevin L; French Vasculitis Study Group.

Arthritis Rheum. 2013 Jan;65(1):270-81. doi: 10.1002/art.37721.

15.

Platelet count kinetics following interruption of antiretroviral treatment.

Zetterberg E, Neuhaus J, Baker JV, Somboonwit C, Llibre JM, Palfreeman A, Chini M, Lundgren JD; INSIGHT SMART Study Group.

AIDS. 2013 Jan 2;27(1):59-68. doi: 10.1097/QAD.0b013e32835a104d.

16.

Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy.

Gasnault J, Costagliola D, Hendel-Chavez H, Dulioust A, Pakianather S, Mazet AA, de Goer de Herve MG, Lancar R, Lascaux AS, Porte L, Delfraissy JF, Taoufik Y; ANRS 125 Trial Team.

PLoS One. 2011;6(6):e20967. doi: 10.1371/journal.pone.0020967. Epub 2011 Jun 30.

17.

Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers.

Simon A, Warszawski J, Kariyawasam D, Le Chenadec J, Benhammou V, Czernichow P, Foissac F, Laborde K, Tréluyer JM, Firtion G, Layouni I, Munzer M, Bavoux F, Polak M, Blanche S; ANRS French Perinatal Cohort Study Group.

JAMA. 2011 Jul 6;306(1):70-8. doi: 10.1001/jama.2011.915.

PMID:
21730243
18.

Previous antiretroviral therapy for prevention of mother-to-child transmission of HIV does not hamper the initial response to PI-based multitherapy during subsequent pregnancy.

Briand N, Mandelbrot L, Blanche S, Tubiana R, Faye A, Dollfus C, Le Chenadec J, Benhammou V, Rouzioux C, Warszawski J; ANRS French Perinatal Cohort (ANRS EPF-CO-01).

J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):126-35. doi: 10.1097/QAI.0b013e318219a3fd.

PMID:
21436712
19.

Host factors and portal of entry outweigh bacterial determinants to predict the severity of Escherichia coli bacteremia.

Lefort A, Panhard X, Clermont O, Woerther PL, Branger C, Mentré F, Fantin B, Wolff M, Denamur E; COLIBAFI Group.

J Clin Microbiol. 2011 Mar;49(3):777-83. doi: 10.1128/JCM.01902-10. Epub 2010 Dec 22.

20.

Campylobacter fetus subspecies fetus spondylodiscitis.

Chaillon A, Baty G, Lauvin MA, Besnier JM, Goudeau A, Lanotte P.

J Med Microbiol. 2010 Dec;59(Pt 12):1505-8. doi: 10.1099/jmm.0.023382-0. Epub 2010 Aug 12.

PMID:
20705728

Supplemental Content

Loading ...
Support Center